Ann: Fast Track granted by US FDA for Efti in 1st line NSCLC, page-21

another thing for consideration: we have not heard of Mercks contribution to these trials....
Initially Immutep had a collaboration with merck for supply of $18M of keytruda but that was years ago
and from memory it was for melanoma......
We have not heard anything else of monetisation in regard to mercks contribution to HNC or NSCLC if indeed
any, we only know we have a combo of keytruda and efti so without knowing any better one would have to
think immutep are buying keytruda retail...
I doubt this is case but let it go until now, I sort of thought we could handle the purchase of keytruda for HNC trials maybe,
but in my mind I can't see immutep being able to buy it for NSCLC without seriously putting a hole in its bank account...